Géraldine Gontier & Grace Kim will be presenting insights from the VGCS-50635-002 study

At NEALS, Géraldine Gontier & Grace Kim will be presenting insights from the VGCS-50635-002 study, where we are investigating the small molecule PIKfyve inhibitor VRG50635 as a potential treatment for all forms of ALS. We look forward to sharing more info on how we recently identified Glycoprotein non-metastatic melanoma protein B (GPNMB) as a key pharmacodynamic biomarker of PIKfyve inhibition. We believe this marks an important step in our mission to bring innovative treatments to ALS patients.